Laura Naranjo Selected Research

Laura Naranjo Research Topics

Disease

6	Autoimmune Diseases of the Nervous System 01/2024 - 01/2021
5	Encephalitis (Encephalitis, Rasmussen) 12/2023 - 01/2021
4	COVID-19 01/2023 - 01/2021
4	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2022 - 01/2018
2	Alzheimer Disease (Alzheimer's Disease) 01/2024 - 01/2023
2	Brain Diseases (Brain Disorder) 12/2023 - 01/2022
2	Glioma (Gliomas) 01/2022 - 01/2021
2	Thrombosis (Thrombus) 01/2021 - 01/2019
2	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 07/2020
1	Multiple Sclerosis 04/2024
1	Paraneoplastic Cerebellar Degeneration 10/2023
1	Melanoma (Melanoma, Malignant) 10/2023
1	Communicable Diseases (Infectious Diseases) 06/2023
1	Malaria 06/2023
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023
1	Cognitive Dysfunction 01/2023
1	Anti-N-Methyl-D-Aspartate Receptor Encephalitis 01/2023
1	Dystonic Disorders (Writer's Cramp) 02/2022
1	Inflammation (Inflammations) 01/2022
1	Neurologic Manifestations (Neurological Manifestations) 01/2022
1	Livedo Reticularis 01/2022
1	Leukopenia 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Scorpion Stings 11/2021
1	Myoclonus (Nocturnal Myoclonus) 01/2021
1	Atrial Fibrillation 01/2021
1	Thymoma (Thymic Carcinoma) 01/2021
1	Ischemic Stroke 01/2021
1	Progressive Encephalomyelitis with Rigidity 01/2021
1	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 01/2021
1	Stroke (Strokes) 01/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Rheumatic Diseases (Rheumatism) 07/2020
1	Gastroenteritis 01/2017
1	Facial Paralysis (Facial Palsy) 01/2017
1	Pulmonary Infarction 01/2017
1	Otitis Media 01/2017
1	Neutropenia 01/2017
1	Diarrhea 01/2017

Drug/Important Bio-Agent (IBA)

15	AntibodiesIBA 01/2024 - 01/2019
4	Immunoglobulin M (IgM)IBA 01/2022 - 01/2018
4	Immunoglobulin G (IgG)IBA 01/2022 - 01/2018
4	Antiphospholipid AntibodiesIBA 01/2022 - 01/2018
3	Antigen-Antibody Complex (Immune Complex)IBA 01/2022 - 01/2018
3	AntigensIBA 01/2022 - 01/2021
3	Immunoglobulin A (IgA)IBA 04/2021 - 11/2020
2	Oligoclonal BandsIBA 04/2024 - 01/2022
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2022
2	CytokinesIBA 01/2022 - 01/2021
2	Leucine (L-Leucine)FDA Link 01/2022 - 01/2021
2	Prothrombin (Factor II)IBA 04/2021 - 01/2021
1	SynucleinsIBA 01/2024
1	Chloroquine (Aralen)FDA LinkGeneric 06/2023
1	Surface Antigens (Surface Antigen)IBA 01/2023
1	amphiphysinIBA 02/2022
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2022
1	14-3-3 Proteins (14-3-3 Protein)IBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Interleukin-18 (Interleukin 18)IBA 01/2022
1	anti-leucine-rich glioma-inactivated 1 autoantibodyIBA 01/2022
1	Interleukin-8 (Interleukin 8)IBA 01/2022
1	Antivenins (Antivenoms)IBA 11/2021
1	GABA Receptors (GABA Receptor)IBA 01/2021
1	Interleukin-2 (IL2)IBA 01/2021
1	PhosphatidylserinesIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	CoagulantsIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	AcidsIBA 01/2021
1	Glycine Receptors (Glycine Receptor)IBA 01/2021
1	Interleukin-15 (Interleukin 15)IBA 01/2021
1	Semaphorin-3AIBA 01/2021
1	metabotropic glutamate receptor 3 (mGluR3)IBA 01/2021
1	Antinuclear AntibodiesIBA 07/2020
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2019
1	SuspensionsIBA 01/2017
1	VaccinesIBA 01/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2017

Therapy/Procedure

2	Therapeutics 12/2023 - 11/2021